Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET

The aim of this study was to evaluate the use of 124I positron emission tomography (PET) to determine the dosimetry of radioiodine therapy in hyperthyroidism and thyroid cancer. Phantom studies to assess the accuracy of PET were performed using an EEC phantom with spheres of different diameters filled with 3-30 MBq of 124I. Patient dosimetry was derived from PET data obtained 1-13 days after simultaneous oral administration of a therapeutic dose of 131I and a diagnostic dose of 124I. The obtained data were compared with findings from intratherapeutic probe measurements and clinical outcome. The phantom studies confirmed that 124I can be quantitated by PET (imprecision < or =10%), and volumetry is feasible for nodules <13 mm (imprecision < or =20%). Any influence of contamination with 123I or the simultaneous administration of 131I on the accuracy of the PET quantification and the probe measurements was ruled out by phantom measurements with solutions of 131I, 124I and 123I in various ratios. In autonomous nodular goitres, radioiodine uptake measured by PET varied from 25.4% to 64.3% and was not significantly different from that obtained by a scintillation probe (24.1%-73.1%, correlation coefficient r=0.91). Comparison of uptake and effective half-life in normal tissue versus autonomous nodules revealed significant differences in uptake but not in effective half-life [uptake 2.0-8.3 kBq/(ml x MBq) in normal tissue vs 12.6-29.3 kBq/(ml x MBq) in nodules; half-life 97.8-156.7 h in normal tissue vs 73.3-192.3 h in nodules]. Calculated radiation doses ranged between 177 and 633 Gy for autonomous nodules and between 47 and 126 Gy for normal tissue. In thyroid cancer patients, doses between 350 and 1,420 Gy were achieved in thyroid remnants and between 70 and 170 Gy in tumour metastases. It is concluded that 124I and PET are suitable for evaluation of the dosimetry of radioiodine therapy in benign and malignant thyroid diseases. The applied technique might be particularly useful for quantitative dose-response studies in radioiodine treatment and further investigations of stunning phenomena.     

Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer

This study seeks to evaluate the role of radioiodine in the ablation of the remaining thyroid lobe, following a histopathological diagnosis of minimally invasive follicular carcinoma or papillary carcinoma of > or =1.5 cm size in patients undergoing hemithyroidectomy. There were 93 patients (69 females and 24 males) with an average age of 37.3+/-12.5 years (range, 16-70 years) and a mean follow-up duration of 46 months. Sixty-six of the patients had papillary cancer and remaining 27 had follicular thyroid cancer. The mean 24 h radioiodine neck uptake at the first visit was 17.2+/-7.3% (4.4-34%). In view of the large amount of thyroid tissue to be ablated, which may produce radiation induced thyroiditis, low doses of radioiodine (15-60 mCi) were administered to the patients. The patients were evaluated 6 months after radioiodine therapy with a 131I whole-body scan and 48 h radioiodine neck uptake, and a thyroglobulin assay after 4-6 weeks of levothyroxine withdrawal. The thyroid lobe was completely ablated in 53 patients (56.9%) after one dose of I and the remaining patients had partial thyroid ablation, with the mean radioiodine neck uptake being reduced to 3.1+/-2.4%. The mean first dose of 131I was 31.8+/-11.7 mCi; the estimated mean absorbed dose was 251.3+/-149.3 Gy (range, 120-790 Gy). Around 30% patients, in each of whom a remnant thyroid lobe was ablated with a single dose of radioiodine, received < or =200 Gy. The cumulative ablation rate was 92.1% after two doses of 131I. Only seven patients needed a third dose of 131I. In our cohort, 15 patients (16.1%) complained of throat discomfort and neck pain. All of them were managed with mild analgesics except three patients who needed additional oral prednisolone for 7-10 days to overcome neck oedema. We conclude that, although completion thyroidectomy remains the standard treatment after hemithyroidectomy in cases of differentiated thyroid cancer, radioiodine ablation of an intact thyroid lobe is possible and it can be achieved with much smaller doses of radioiodine than previously believed. Lobar ablation is an attractive alternative to surgery for those who refuse to undergo completion thyroidectomy or had complications during initial surgery. However, the long-term outcome in this subset of patients remains to be determined.     

Thyroid uptake error in four different gamma camera systems

The thyroid uptake of (123)I and (131)I is generally measured by a gamma camera system. We evaluated the error in determining thyroid uptake caused by different methods of calculation among four gamma camera systems with various collimators. We first designed an original thyroid phantom that consisted of the thyroid and a body containing various levels of radioiodine activity. The applications for thyroid uptake equipped in two gamma camera systems performed calculations by the automatic method with background counts not subtracted from the capsule counts. When the size of the rectangular region of interest (ROI) for the capsule was set at 10x8 cm (a typical ROI size for the thyroid), percentages of thyroid uptake as calculated by the manual method with background counts subtracted from the capsule counts and thyroid counts were 52% to 57% when the value was set at 55% for (123)I; and 54.2% and 58.7%, respectively, when the value was set at 60% for (131)I. On the other hand, the percentages of thyroid uptake calculated by the automatic method with the application using two gamma camera systems with non-subtraction of background counts from the capsule counts were 46% and 50.5% when the value was set at 55%; and 49.6% when the value was set at 60%. The values calculated by the automatic method were underestimated as a result of background counts that were not subtracted from the capsule counts. When ROI size for the capsule was set at 4x4 cm, which is slightly larger than the capsule size, even thyroid uptake as determined by the automatic method using the application showed a difference of less 2% from the set values. There was no difference in thyroid uptake among the various kinds of collimators, high-resolution collimators, all-purpose collimators, and a suitable collimator for gamma-ray energy of (123)I.     

Quantification of absorbed doses to urine bladder depending on drinking water during radioiodine therapy to thyroid cancer patients: a clinical study using MIRDOSE3

The object of the study was to quantify the absorbed doses to urinary bladder using MIRDOSE3 (medical internal radiation dose package program) depending on drinking water after giving radioiodine dose to thyroid cancer patients. Twenty-nine female thyroid cancer patients (aged 40-60 years, mean 50 years) were selected. The therapeutic doses ranged from 3700 to 7400 MBq of 131I. The radioiodine uptake was measured at 1 cm distance from three organs (previously marked), the thyroid, thigh and stomach, by using a calibrated Eberline ESP-2 GM counter, with a special arrangement of each patient. Urine samples were collected every 12 h for first 72 h, and then every 24 h for the next 96 h. The individual biological half-life of excreted urine was calculated using individual effective half-life. Absorbed doses were calculated for an adult female phantom using the dynamic bladder model of MIRDOSE3 program in two phases: firstly, for different voiding intervals; and secondly, depending on individual drinking water. An average of 85% of the total dose passed through the urinary tract within the first 72 h, with a biological half-life of 28.5+/-0.747 h, and 9% for the next 96 h with a biological half life of 118.43+/-0.645 h. The voiding interval shows great impact on total absorbed dose to bladder and water supplementation needs to be intensified to reduce absorbed doses to bladder wall for the first 3 days.     

Simple, rapid thyroid function testing with 99mTc-pertechnetate thyroid uptake ratio and neck/thigh ratio.

To avoid the technical difficulties and errors inherent in the measurement of early thyroid uptake of 99mTcO4-,techniques which are independent of absolute uptake, neck extrathyroidal background and dose standards were evaluated in a series of 108 patients. After intravenous injection of 2 mCi 99mTcO4-, radioactivity was recorded over the neck and thigh. Thyroid uptake ratios were calculated as the ratios of activity over the neck at two times. A neck/thigh ratio was calculated from the recorded activities at 15 min after injection. Examination of these parameters showed that a combination of the 15 min neck/thigh ratio and the 10'/2' thyroid uptake ratio best served to discriminate thyroid function: 92% of hyperthyroid cases were correctly identified by a neck/thigh ratio above 4.7 and 95% of hypothyroid cases were identified by the combination of a neck/thigh ratio below 3 and a 10'/2' thyroid uptake ratio below 1. Correct classification of euthyroidism was 84% but with the exclusion of patients previously treated with 131I, this rose to 91%. The accuracy of the 99mTc procedure is comparable to that of the standard 24 hr 131I uptake run concurrently in this series and duplicates the accuracy of computer assisted determinations of absolute thyroid 99mTcO4- uptakes. The procedure provides a convenient method for the evaluation of thyroid function as an accompaniment to 99mTcO4- thyroid imaging.     

Value of technetium scintigraphy and iodine uptake measurement during follow-up of differentiated thyroid cancer

Measurement of serum thyroglobulin (Tg) levels and I-131 whole body scintigraphy (WBS) are used in the follow-up of patients with differentiated thyroid cancer (DTC). This study was designed to evaluate the significance of persistent I-131 uptake in the thyroid bed in patients with DTC following surgery and/or radioactive iodine ablation. Tc-99m thyroid scintigraphy (TS) and I-131 thyroid uptake (IU) were also performed to determine their clinical impact on patient management. PATIENTS AND METHODS: Sixty-two non-metastatic patients (14 men, 48 women) with a mean age of 44 years (range: 16-75) who had undergone surgical thyroidectomy for DTC were evaluated prospectively. All patients had undergone technetium and iodine scintigraphy (IS). Although serum Tg levels were measured in all patients, IU was available in 36. RESULTS: Tg values were in the range of 0.2-24 ng/ml (median: 0.2 ng/ml) when patients were in the hypothyroid state. I-131 WBS detected residual tissue in the neck in 30 patients (48%); however TS was positive in only 12 (19%). I-131 uptake in the thyroid bed ranged from 0 to 14% (median: 0.1%). Twelve of 13 patients with positive IS and negative TS had uptake values < or = 0.3% (p < 0.00001). When IU values were < or = 0.3%, 54% of our patients did not have any uptake in the thyroid bed on TS or IS, whereas when IU was > 0.3%, 80% of patients had neck uptake on both TS and IS (p < 0.00001). CONCLUSION: The results of this study demonstrate that the concordance of IS and TS depends on the IU level after suspension of replacement therapy. Measurements of IU and TS are of considerable value in evaluating patient response to therapy and will substantially reduce the need for repetitive radioiodine scans and unnecessary treatment doses in patients with undetectable Tg values.     

CT扫描所致受检者器官剂量的体模实验研究

目的 了解不同部位X射线CT扫描所致受检者器官或组织的吸收剂量及其分布。方法 实测体模中重要组织器官的CT值,并转换成线性吸收系数与人体正常值进行比较;在体模中 布放光致辐射发光玻璃剂量计,分别模拟测量头部、胸部、腹部和盆腔CT扫描所致受检者主要器官或组织的吸收剂量。结果 实验用仿真人体模具有良好的组织等效性。头部扫描吸收剂量最大的器官是大脑,胸部扫描吸收剂量较大的器官是甲状腺、乳腺、肺和食道,腹部扫描吸收剂量较大的器官是肝、胃、结肠和肺,单次盆腔扫描体所致骨表面和结肠的吸收剂量可达50 mGy以上。结论 X射线CT扫描所致受检者的器官剂量及其分布随扫描部位的不同而异。盆腔扫描时结肠、红骨髓、性腺和膀胱等主要器官的吸收剂量较大,应引起注意。     

Patient radiation dose at CT urography and conventional urography

PURPOSE: To measure and compare patient radiation dose from computed tomographic (CT) urography and conventional urography and to compare these doses with dose estimates determined from phantom measurements. MATERIALS AND METHODS: Patient skin doses were determined by placing a thermoluminescent dosimeter (TLD) strip (six TLD chips) on the abdomen of eight patients examined with CT urography and 11 patients examined with conventional urography. CT urography group consisted of two women and six men (mean age, 55.5 years), and conventional urography group consisted of six women and five men (mean age, 58.9 years). CT urography protocol included three volumetric acquisitions of the abdomen and pelvis. Conventional urography protocol consisted of acquisition of several images involving full nephrotomography and oblique projections. Mean and SD of measured patient doses were compared with corresponding calculated doses and with dose measured on a Lucite pelvic-torso phantom. Correlation coefficient (R(2)) was calculated to compare measured and calculated skin doses for conventional urography examination, and two-tailed P value significance test was used to evaluate variation in effective dose with patient size. Radiation risk was calculated from effective dose estimates. RESULTS: Mean patient skin doses for CT urography measured with TLD strips and calculated from phantom data (CT dose index) were 56.3 mGy +/- 11.5 and 54.6 mGy +/- 4.1, respectively. Mean patient skin doses for conventional urography measured with TLD strips and calculated as entrance skin dose were 151 mGy +/- 90 and 145 mGy +/- 76, respectively. Correlation coefficient between measured and calculated skin doses for conventional urography examinations was 0.95. Mean effective dose estimates for CT urography and conventional urography were 14.8 mSv +/- 90.0 and 9.7 mSv +/- 3.0, respectively. Mean effective doses estimated for the pelvic-torso phantom were 15.9 mSv (CT urography) and 7.8 mSv (conventional urography). CONCLUSION: Standard protocol for CT urography led to higher mean effective dose, approximately 1.5 times the radiation risk for conventional urography. Patient dose estimates should be taken into consideration when imaging protocols are established for CT urography.     

Pediatric patient exposures from CT examinations: GE CT/T 9800 scanner

This report presents Computed Tomography Dose Index (CTDI) values for typical CT examinations of children for a GE CT/T 9800 scanner and compares them with measured entrance skin absorbed doses of pediatric patients under clinical situations. Pediatric entrance skin absorbed doses were 1.1-2.4 rad (cGy) for chest and abdomen examinations, 2.0-3.4 rad (cGy) for pediatric head examinations, and 3.2-4.2 rad (cGy) for infant (less than or equal to 6 months) head examinations. CTDI measurements in a cylindrical Lucite head phantom predicted typical pediatric absorbed doses to within about 5% for chest and abdomen examinations and to within about 15% for head examinations, when corrections for amperage differences are taken into account.     

Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies

PURPOSE: To retrospectively compare the sensitivity of a dedicated fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) protocol versus a standard whole-body PET/CT protocol for detection of head and neck cancer, with biopsy and follow-up as reference standards. MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained for this HIPAA-compliant study. Dedicated and standard PET/CT protocols were performed in a phantom and in 55 patients suspected of having head and neck cancer (28 men, 27 women; age range, 21-79 years). The neck phantom contained four 4.4-9.8-mm-diameter spheres. Standard protocol consisted of a midcranium to proximal thigh emission scan of 2-4 minutes per bed position. Dedicated protocol was an 8-minute head and neck scan. Reconstructed field of view and pixel size, respectively, were 30 cm and 2.34 mm for the dedicated and 50 cm and 3.91 mm for the standard protocol. FDG uptake was evaluated visually and semiquantitatively by using standardized uptake values (SUVs). Mean SUV was compared between dedicated and standard protocols with a t test modified for clustered sampling. Receiver operating characteristic (ROC) curves were calculated. A two-tailed P value was used. RESULTS: In the phantom study, a larger percentage difference (20%-27%) in sphere-to-background ratios with the dedicated than with the standard protocol was observed for 6.0-9.8-mm spheres. In the clinical study, a total of 149 lymph nodes were identified. Five malignant and six benign lymph nodes (mean diameter, 7.1 mm) were visually identified with the dedicated protocol only. SUVs with the dedicated protocol were significantly higher than those with the standard protocol (P<.001). Area under the ROC curve was 0.94 for the dedicated and 0.92 for the standard protocol (P=.56). CONCLUSION: FDG PET with either the standard or dedicated protocol was more sensitive than CT for evaluating head and neck lymph nodes. The dedicated protocol improved the detectability of smaller nodes.     

单纯CT伪影对放疗剂量计算的影响

目的 通过人为制造CT伪影,来研究实际临床操作中单纯伪影对放疗剂量计算的影响。方法 对替换钛合金组件前后的模体进行CT扫描,统计替换前后不同位置的CT值;将钛合金区域的CT值修正为水模体的CT值,并采用Varian的各向异性分析算法（AAA）、Acuros XB （AXB）算法和Pinnacle系统的筒串卷积算法（CCC）3种算法,对替换钛合金组件前后的模体进行剂量计算,统计替换前后不同位置的绝对剂量值,并进行分析。结果 Varian和Pinnacle系统对评价CT值大小比较一致。对于均匀模体,CT值偏差30 HU以下时,3种不同的算法在距离体表0.5 cm时,剂量偏差最大达到12.0%,最小为6.0%;1.5 cm以上偏差的绝对值均<1.0%。对于肺部模体来说,Varian的AAA算法和AXB算法在CT值相差15 HU的情况下,剂量值相差在1.0%左右;但Pinnacle系统的CCC算法在同样情况下剂量值相差较大,相差5.0%左右。结论 CT伪影对放疗剂量计算存在明显影响,导致组织剂量分布发生变化,可能造成浅部肿瘤照射剂量不足,深部肿瘤过量照射。     

Influence of patient age on normalized effective doses calculated for CT examinations

Monte Carlo simulations of CT examinations have been performed to estimate effective doses, normalized to axial air kerma, for six mathematical phantoms representing ages from newborn to adult, and for three CT scanner models covering a range of designs. Organ doses were calculated for CT exposures of contiguous, 1 cm wide, transverse slices in each phantom and summed to give normalized effective doses for scans of four regions of the trunk and head. In all cases an inverse trend is observed between normalized effective dose and phantom age, with the dose to the newborn from head and neck scans being 2.2-2.5 times higher than that to the adult, depending on scanner model. Corresponding increases for scans of the trunk region are more variable between scanners and range from a factor of 1.3 to 2.4. If typical clinical exposure conditions for adults are also utilized for children, then, for example, the effective dose to the newborn from a chest scan could be above 15 mSv. It is concluded that CT has the potential to deliver significantly greater radiation doses to children than to adults and in view of their greater susceptibility to radiation effects, special efforts should be made in clinical practice to reduce doses to children by the use of size-specific scan protocols.     

'Early' thyroid 123I uptake: correction for extrathyroidal neck radioactivity.

Should one correct for extrathyroidal neck radioactivity ('neck background') when interpreting perchlorate discharge test results? A new background correction method was developed using a linear probe. 123I produces photon peaks at two energy levels: 159 keV (gamma-rays) and 28 keV (X-rays), with an attenuation of 15 and 35% per cm water, respectively. If one fixes the position of the subject's neck, radiation from thyroid 123I produces an X/gamma detection ratio (alpha) which is constant and, due to the anterior localization of the thyroid, higher than the ratio (beta) produced by extrathyroidal 123I. These two ratios can be determined in vivo and used to calculate background-corrected and depth-corrected thyroid uptake. In simulation experiments our method was effective so long as the 'gland' was situated close enough to the 'neck' surface for the difference (alpha-beta) to be less than 0.19. Perchlorate discharge tests were performed in five euthyroid subjects who were pretreated with methimazole. The difference (alpha-beta) ranged from 0.27 to 0.36. Uncorrected, the mean discharge was 57% (range 47-66); corrected, it was 92% (range 88-94). In 15 hyperthyroid Graves' patients, with goitres varying from 13 to 63 ml, alpha-beta ranged from 0.22 to 0.40 and was unrelated to goitre size. The contribution of neck background is quantitatively important, especially when thyroid uptake is low; our new method corrects for it, even with large goitres.     

Reference range determination: the problem of small sample sizes.

The process of developing and validating a quantitative test includes determination of a reference range. Traditionally this has been taken as the mean +/- 2 standard deviations for a random sampling from a reference population. However, this method fails to recognize the substantial variability in the sample mean and standard deviation for the small sample sizes frequently encountered in nuclear medicine. A new approach, which involves calculating confidence intervals for the upper and lower bounds of the traditionally defined range, recognizes three ranges of values: normal, indeterminate, and abnormal. The principles of this approach are illustrated using differential renal function in twelve renal transplant donors. The 99mTc-DTPA differential uptake between 1 and 2 min gave a traditionally-defined single-kidney range of 50% +/- 8%, whereas with our method the normal range would be 50% +/- 6% with indeterminate ranges of 37%-44% and 56%-63%. These values are consistent with the wide variation in reference ranges reported in the literature, and suggest that much of this variability may be a statistical artifact resulting from inadequate sample sizes. A nomogram has been derived that permits the power of the reference range determination to be easily calculated from the sample size. Analysis of the effect of sample size on the accuracy of the upper and lower bounds of the reference range is advocated whenever small reference populations are used.     

Influence of various geometric factors on the iodine-131 uptake measurement for solitary thyroid nodules

AIM: The influence of various geometric factors on I uptake measurements for solitary thyroid nodule was systematically investigated to derive an approach, based on routinely performed ultrasound examinations, to correct for the effect of geometric variations. METHODS: The influence of size, shape, and position of a thyroid nodule, neck-to-detector distance and neck curvature on the uptake value was analyzed with a three-dimensional model. Uptake measurements using a tissue-equivalent neck phantom were carried out to verify the calculated correction factors and also to check the influence of scatter. Sonograms of 92 patients with solitary nodules were analyzed to correct for geometric variations. RESULTS: The correction factors were independent of the size and shape of the nodule, and the activity distribution of the solitary nodules can be approximated by a point source. The correction factors were mainly determined by the nodular depth and by the accuracy of the neck-to-detector distance and were affected to a lesser extent by the lateral position of the nodule as well as the curvature of the neck. The effect of scatter can be neglected if the energy window largely excludes Compton scatter, as is the case in the I uptake measurement. The ultrasound-derived correction factors ranged from 0.85 to 1.25. CONCLUSION: The proposed approach is capable of correcting for the geometric variation for a solitary nodule and can be easily applied in routine clinics. The accuracy of absorbed dose in radioiodine therapy can be improved in particular for nodules located well beneath the neck surface.     

Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake

The aim of this study was to optimise radioiodine therapy of diffuse and nodular toxic goitre by calculation of the radiation dose delivered to the thyroid on the basis of the pretreatment technetium-99m pertechnetate thyroid uptake under thyrotropin suppression (TcTU(s)). The TcTU(s) value serves as a substitute for the non-suppressible iodine turnover and the functional autonomous mass. Marinelli's formula was used to calculate tissue absorbed doses of 150 Gy, 200 Gy, 250 Gy and 300 Gy to the thyroids of 438 patients with multifocal and disseminated autonomy. The mean age of patients was 70+/-9 years, and the mean thyroid volume was 54+/-26 ml. Two hundred and sixty-one of the patients had at least one documented previous episode of overt hyperthyroidism. Tissue absorbed doses were adapted to the pretreatment TcTU(s): 150 Gy for a TcTU(s) of 1.5%-2.49%, 200 Gy for a TcTU(s) of 2.5%-3.49%, 250 Gy for a TcTU(s) of 3.5%-4.49% and 300 Gy for a TcTU(s) of > or =4.5%. Normalisation of TcTU(s) and thyrotropin (TSH), thyroid volume reduction and frequency of hypothyroidism and recurrent hyperthyroidism were evaluated 1 year after a single radioiodine therapy. The presented dose strategy resulted in normalisation of TcTU(s) in 96% and an increase in TSH to the normal range in 92%. Recurrent hyperthyroidism was observed in only five patients. Thyroid volume decreased from 54+/-26 before treatment to 34+/-20 ml, a mean reduction of 37%. The frequency of hypothyroidism, at 0.9%, was encouragingly low. Dose selection in accordance with pretreatment TcTU(s) can be recommended for elimination of functional autonomous tissue with a single radioiodine therapy in patients of advanced age with enlarged thyroid glands and relevant autonomous masses who are at risk of developing iodine-induced hyperthyroidism.     

二极管半导体探测器(Diode)测量放射治疗患者剂量方法的研究

目的 研究用Diode探测器测量光子线束治疗中患者接受剂量的方法,验证治疗计划系统(TPS)计算剂量,并与Diode探测器测量剂量进行比较.方法 用60Coγ射线、6 MV X射线、水模体和固体模体,开展Diode探测器的重复性、剂量率响应、非线性剂量响应及刻度因子等实验.根据临床治疗需要,选择在不同条件下,研究剂量随机器角度、能量响应、源皮距、照射野、楔形角度、挡块和托盘因子等变化的影响,求出Diode探测器校准因子,用仿真人模体、Diode探测器、6 MV X线束,验证骨盆、头颈等部位剂量.再用Diode探测器测量6 MV X射线照射9例放疗患者的头颈、胸及腹等部位的剂量.结果 仿真人模体骨盆前面,左、右两侧(加楔形和不加楔形角度),以及头颈部左、右两侧(戴面具和不带面具)条件下,Diode测量值与TPS计算值的相对偏差均在±3%以内;放疗患者的头颈部两侧(戴面具)、胸部及腹部,Diode测量值与TPS计算值的相对偏差均在±5%以内.结论 用Diode探测器验证放疗患者剂量方法准确可靠,能快速获得数据.

Abstract：

Objective To explore the measurement method of the treatment dose of the patient with Diode for photon beam in radiotherapy,and to validate the treatment dose by comparing with the treatment planning system (TPS).Methods Experiments of the reproducibility,dose rate dependence,non-linearity dose response,and calibration factor in 60Co γ and 6 MV X beams were carried out with Diode on the surface of solid phantom and in water phantom.According to the needs of clinic treatment,different conditions were chosen to observe the dose changes with the angle of incidence,energy response,distance of source to skin,field size,wedge angle,block and tray using ionization chamber and water phantom.The Diode was placed on the surface of the solid phantom to obtain the correction factors.The doses of the chest,abdomen,and head and neek were verified with the Alderson phantom and Diode.Diode doses of the pelvis,head and neck at 14 points on the patient were measured.Results The Diode was irradiated at the points of the Alderson phantom,such as AP,RL and LL of the pelvis,with and without wedges,RL and LL junction of the neck and chin,with and without mask,the maximum relative deviation of doses was within ± 3% between Diode and TPS.The Diode was placed in different locations on the patient,including chest,abdomen and head and neck.The relative maximum deviation of doses was within ±5% between Diode and TPS.Conclusions The Diode method is reliable for measuring the exposure doses of the patient in radiotherapy.     

A comparative study of thoracic radiation doses from 64-slice cardiac CT

The goal of this study was to measure radiation doses for 64-slice cardiac CT angiography studies and to study the dose-savings features of these CT scanners. This was done using various phantoms. These radiation doses were compared with those from typical helical body CT scans, fluoroscopy cardiac catheterization studies and mammography examinations. Radiation measurements were made with a CT ionization detector and a solid state dosimeter. A GE 64-slice Lightspeed VCT and a Siemens Somatom Sensation 64 CT were used to scan a standard 32 cm acrylic phantom and an anthropomorphic phantom. Data were collected in axial and various gated cardiac helical modes. Organ doses and the effective doses were calculated from the measurements. In gated CT cardiac mode with the 32 cm acrylic phantom, the measured radiation doses per study were generally three to seven times greater than those from typical body helical CT examinations; the range depended upon selectable scan parameters. With the anatomical phantom, the surface doses in the anteroposterior (AP) plane were typically 20-60% higher than those measured using the 32 cm phantom. The lateral surface doses were -4% to +15%. These results can be attributed to the shorter AP dimension and the air in the lungs. The CT skin entrance radiation doses were 80-90% less than diagnostic cardiac catheterization studies, and organ doses were similar. Because 64-slice cardiac gated CT uses pitches equal to 0.20-0.27 and high mAs values, the patient radiation doses are appreciably higher than in routine body CT examinations. The female breast, which could receive a radiation dose 10-30 times that received from mammography screening, is an organ of particular concern.     

Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy

In our hospital, a 24-h radioiodine-131 (¹³¹I) uptake-related ablation strategy is used in patients with differentiated thyroid cancer to destroy thyroid remnants after primary surgery. In this strategy, low doses of ¹³¹I are used, but data in the literature on its efficacy are conflicting. Therefore, we performed the present study to evaluate the clinical outcome of this ablation strategy. In this study, patients (n=235) were selected who underwent thyroidectomy for differentiated thyroid cancer, followed by an ablative dose of ¹³¹I. Approximately 6 months after ablation, treatment efficacy was evaluated using radioiodine scintigraphy and thyroglobulin (Tg) measurements. Successful ablation was defined as the absence of radioiodine uptake in the neck region (criterion 1). Tg values were determined 3–12 months after ablation (criterion 2). Based on criterion 1, unsuccessful ablation was found in 43.0% of cases. Pre-treatment uptake values were statistically significantly lower (P=0.003) in successfully ablated patients (mean 5.4%) than in unsuccessfully ablated patients (mean 8.2%). Based on criterion 2, unsuccessful ablation was found in 52.4% of patients. The uptake-related ablation strategy, using low doses of ¹³¹I, shows a relatively high treatment failure rate. Based on these results it is suggested that a lower ablation failure rate could be achieved by applying higher ¹³¹I doses in the ablation of thyroid remnants in differentiated thyroid carcinoma patients. In the case of lymph node metastases a further dose adjustment may be advisable.